Oxygen-independent degradation of HIF-α via bioengineered VHL tumour suppressor complex

EMBO Molecular Medicine

Volumn 1, Issue 1, 2009, Pages 66-78

  Sufan, Roxana I ^a   Moriyama, Eduardo H ^b   Mariampillai, Adrian ^b   Roche, Olga ^a   Evans, Andrew J ^a,b   Alajez, Nehad M ^b   Vitkin, I Alex ^b   Yang, Victor X D ^b,c   Liu, Fei Fei ^b   Wilson, Brian C ^b   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c RYERSON UNIVERSITY   (Canada)

Author keywords

Angiogenesis; ARNT; HIF; Renal cell carcinoma; VHL

Indexed keywords

AD EGFP T7 HPACGV VECTOR; AD EGFP T7 VHL VECTOR; AD EGFP VECTOR; ADENOVIRUS VECTOR; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR; OXYGEN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOENGINEERING; CANCER GROWTH; CANCER RESISTANCE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE CONSTRUCT; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OXYGEN TENSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RADIOSENSITIVITY; SCID MOUSE; SKINFOLD; TUMOR REGRESSION; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BIOENGINEERING; CARCINOMA, RENAL CELL; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GREEN FLUORESCENT PROTEINS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MICE; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; PLASMIDS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950216769     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.200900004     Document Type: Article

References (48)

1. Algire GH, Legallais FY (1949) Recent developments in the transparent-chamber technique as adapted to the mouse. J Natl Cancer Inst 10; 225-253 incl 228 pl.
2. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447
3. BrugarolasJ (2007) Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 356: 185-187
4. Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340
5. Chen W, LeeJ,ChoSY, Fine HA (2004) Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res 64: 3949-3957
6. Cockman ME, Masson N,Mole DR,Jaakkola P,Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741
7. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353: 2477-2490
8. Cohen JC, Scott DK, Miller J, Zhang J, Zhou P, Larson JE (2004) Transient in utero knockout (TIUKO) of C-MYC affects late lung and intestinal development in the mouse. BMC Dev Biol 4: 4
9. Cong F, Zhang J, Pao W, Zhou P,Varmus H (2003) A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol 4: 10
10. Costa LJ, Drabkin HA (2007) Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12: 1404-1415
11. Covello KL, Kehler J,Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC, Keith B (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570
12. Duan LJ, Zhang-Benoit Y, Fong GH (2005) Endothelium-intrinsic requirement for Hif-2alpha during vascular development. Circulation 111: 2227-2232
13. Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, Acker T, Rauter M, Plate K, Sieweke M, Breier G, et al (2003) Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278: 7520-7530
14. Epstein AC, GleadleJM, McNeill LA, Hewitson KS, O'RourkeJ, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, et al (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54
15. Evans AJ, Russell RC, Roche O, BurryTN, Fish JE, Chow VW, Kim WY, Saravanan A, Maynard MA, Gervais ML, et al (2007) VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27: 157-169
16. Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DA, Nakamura E, Lorimer IA, Lee S (2003) Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 278: 44966-44974
17. Huang D,Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA, etal (1991) Optical coherence tomography. Science 254: 1178-1181
18. Ivan M, Kondo K,Yang H, Kim W, ValiandoJ, Ohh M, Salic A, AsaraJM, Lane WS, Kaelin WG Jr(2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468
19. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472
20. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, ConawayJW (2000) Activation ofHIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430-10435
21. Kewley RJ, Whitelaw ML, Chapman-Smith A (2004) The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. IntJ Biochem Cell Biol 36: 189-204
22. Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004
23. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr(2003) Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1: E83
24. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WGJr(2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246
25. Liu J, Stevens J, Matsunami N, White RL (2004) Targeted degradation of beta-catenin by chimeric F-box fusion proteins. Biochem Biophys Res Commun 313: 1023-1029
26. Mariampillai A, Standish BA, Moriyama EH, Khurana M, Munce NR, Leung MK, Jiang J, Cable A, Wilson BC,Vitkin IA, et al (2008) Speckle variance detection of microvasculature using swept-source optical coherence tomography. Opt Lett 33: 1530-1532
27. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBOJ 20: 5197-5206
28. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275
29. Maynard MA, Evans AJ, Shi W, Kim WY, Liu FF,Ohh M (2007) Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle 6: 2810-2816
30. Maynard MA, Ohh M (2004) Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 24: 1-13
31. Maynard MA, Ohh M (2007) The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 64: 2170-2180
32. Melillo G (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26: 341-352
33. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427
34. Oudard S, George D, Medioni J, Motzer R (2007) Treatment options in renal cell carcinoma: past, present and future. Ann Oncol 18 (Suppl 10): x25-x31
35. Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, Pierce JW, Podust VN, Luo RS, Chau V, et al (2000) Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha. Mol Cell Biol 20: 2326-2333
36. Roberts AM, Ohh M (2008) Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau. Curr Opin Oncol 20:83-89
37. Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578
38. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732
39. Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug
40. Discov Today 12: 853-859 Stebbins CE, Kaelin WGJr, Pavletich NP (1999) Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284: 455-461
41. Su Y, Ishikawa S, Kojima M, Liu B (2003) Eradication of pathogenic beta-catenin by Skpi/Cullin/F box ubiquitination machinery. Proc Natl Acad Sci USA 100: 12729-12734
42. Sufan RI, Ohh M (2006) Role of the NEDD8 modification of Cul2 in the sequential activation of ECV complex. Neoplasia 8: 956-963
43. Tanimoto K, Makino Y, Pereira T, Poellinger L (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309
44. Tian H, McKnight SL, Russell DW (1997) Endothelial PAS domain protein 1 (EPASi), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82
45. van den Beucken T, Koritzinsky M, Wouters BG (2006) Translational control of gene expression during hypoxia. Cancer Biol Ther 5: 749-755
46. Warnecke C, Zaborowska Z, KurreckJ, Erdmann VA, Frei U, Wiesener M, Eckardt KU (2004) Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18: 1462-1464
47. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, et al (1998) Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92: 2260-2268
48. Zhou P, Bogacki R, McReynolds L, Howley PM (2000) Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell 6: 751-756